INGENIA Therapeutics KRX:950260KOSDAQ
인제니아테라퓨틱스 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days1
DART filings, 7 days4
Articles tracked1since Sep 11
In Q2 2026, INGENIA Therapeutics reported operating profit of ₩0m. INGENIA Therapeutics (인제니아테라퓨틱스) appeared in 1 Korean news article and 4 DART filings over the past seven days. Coverage peaked on Sep 29 with 1 article. The most common catalyst was contracts & orders (1).
Filing signals Turnaround Clinical trial filing Screener
INGENIA Therapeutics quarterly results consolidated, KRW
| Quarter | Operating profit | Net income |
|---|---|---|
| Q2 2026 | ₩0m | ₩0m |
| Q2 2025 | −₩5m | −₩3m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
INGENIA Therapeutics top stories 2 weeks, by number of outlets
- 1